Abstract
Despite improving standards of care, people with diabetes remain at risk of development and progression of diabetic retinopathy (DR) and visual impairment. Identifying novel therapeutic approaches, preferably targeting more than one pathogenic pathway in DR, and at an earlier stage of disease, is attractive. There is now consistent evidence from two major trials, the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study and the Action to Control Cardiovascular Risk in Diabetes Eye (ACCORD-Eye) study, totalling 11,388 people with type 2 diabetes (5,701 treated with fenofibrate) that fenofibrate reduces the risk of development and progression of DR. Therefore, fenofibrate may be considered a preventive strategy for patients without DR or early intervention strategy for those with mild DR. A number of putative therapeutic mechanisms for fenofibrate, both dependent and independent of lipids, have been proposed. A deeper understanding of the mode of action of fenofibrate will further help to define how best to use fenofibrate clinically as an adjunct to current management of DR.
Keywords: Diabetic retinopathy, fenofibrate, mode of action, pathogenesis, type 2 diabetes.
Current Medicinal Chemistry
Title:Fenofibrate: A New Treatment for Diabetic Retinopathy. Molecular Mechanisms and Future Perspectives
Volume: 20 Issue: 26
Author(s): Rafael Simo, Sayon Roy, Francine Behar-Cohen, Anthony Keech, Paul Mitchell and Tien Yin Wong
Affiliation:
Keywords: Diabetic retinopathy, fenofibrate, mode of action, pathogenesis, type 2 diabetes.
Abstract: Despite improving standards of care, people with diabetes remain at risk of development and progression of diabetic retinopathy (DR) and visual impairment. Identifying novel therapeutic approaches, preferably targeting more than one pathogenic pathway in DR, and at an earlier stage of disease, is attractive. There is now consistent evidence from two major trials, the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study and the Action to Control Cardiovascular Risk in Diabetes Eye (ACCORD-Eye) study, totalling 11,388 people with type 2 diabetes (5,701 treated with fenofibrate) that fenofibrate reduces the risk of development and progression of DR. Therefore, fenofibrate may be considered a preventive strategy for patients without DR or early intervention strategy for those with mild DR. A number of putative therapeutic mechanisms for fenofibrate, both dependent and independent of lipids, have been proposed. A deeper understanding of the mode of action of fenofibrate will further help to define how best to use fenofibrate clinically as an adjunct to current management of DR.
Export Options
About this article
Cite this article as:
Simo Rafael, Roy Sayon, Behar-Cohen Francine, Keech Anthony, Mitchell Paul and Wong Yin Tien, Fenofibrate: A New Treatment for Diabetic Retinopathy. Molecular Mechanisms and Future Perspectives, Current Medicinal Chemistry 2013; 20 (26) . https://dx.doi.org/10.2174/0929867311320260009
DOI https://dx.doi.org/10.2174/0929867311320260009 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review of Treatment for Cocaine Dependence
Current Drug Abuse Reviews The Potential Role of Thiamine (Vitamin B1) in Diabetic Complications
Current Diabetes Reviews Pneumonia Due to Methicilin-Resistant Staphylococcus aureus (MRSA): A Review
Current Respiratory Medicine Reviews The Epidermis as a Model for Tissue Engineering
Current Tissue Engineering (Discontinued) Prospectives for Gene Therapy of Retinal Degenerations
Current Genomics Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets Targeted Therapy of Multiple Myeloma: The Changing Paradigm at the Beginning of the New Millennium
Current Cancer Drug Targets Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Current Diabetes Reviews Association between Proliferative Diabetic Retinopathy and Serum Bile Acid Level in Patients with Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Innate Immunity, Toll-Like Receptors, and Diabetes
Current Immunology Reviews (Discontinued) Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine Drug-Induced Peripheral Neuropathy: A Narrative Review
Current Clinical Pharmacology Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery PDE-5 Inhibitors: Clinical Points
Current Drug Targets Monogenic Diabetes: Genetics and Relevance on Diabetes Mellitus Personalized Medicine
Current Diabetes Reviews Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases
Current Signal Transduction Therapy